Loratadine exclusivity
This article was originally published in The Tan Sheet
Executive Summary
Andrx "will accept Wyeth's offer to forsake generic exclusivity" after Aug. 9 and requests FDA adopt "appropriate measures to implement Wyeth's offer" in March 21 comments. In a recent citizen petition, Andrx alleged marketing exclusivity for Wyeth's generic loratadine should start from the Alavert approval date, although Wyeth disputed the assertion (1"The Tan Sheet" March 31, 2003, p. 9). While Andrx accepts Wyeth's "compromise," firm maintains Wyeth's position "cannot be right," because firm "implicitly concedes as much by offering to forsake generic exclusivity 180 days after a date that is before the date on which it will commence" marketing of generic loratadine...